BIOMARIN PHARMACEUTICAL INC (BMRN) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-27

Key Insights

BioMarin completed its acquisition of Amicus Therapeutics for $14.50 per share in cash on April 27, 2026, representing a significant strategic combination in the rare disease pharmaceutical space that expands BioMarin's product portfolio and market presence.
The company financed the Amicus acquisition through $2.8 billion in senior secured term loans ($2.0B Term Loan B and $800M Term Loan A) plus $600M revolving credit facility, with Term B loans maturing in 7 years at 1.75% margin and Term A loans maturing in 5 years at variable margins of 1.00-1.75%.
BioMarin incurred substantial debt to fund the merger, with the company relying on previously issued $500M of 5.500% Senior Notes due 2034 and existing cash, creating meaningful leverage that investors should monitor for deleveraging progress and cash flow impact in future quarters.
All Amicus equity awards were converted to cash payments at the $14.50 merger price, including in-the-money options, RSUs, and performance-vesting RSUs, indicating a complete equity elimination and potential for significant employee transition considerations post-close.

Want the newest filings?

This analysis covers the filing from 2026-04-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-23

French FDI regulatory clearance obtained on April 23, 2026, satisfying the final significant condition to closing the Amicus Therapeutics merger, with expected closing scheduled for April 27, 2026.
The merger agreement with Amicus was signed December 19, 2025, and regulatory approval process has progressed through multiple jurisdictions, indicating sustained momentum toward deal completion.
Remaining conditions to closing are only those customary matters satisfied at closing, substantially de-risking the transaction and reducing uncertainty around deal completion timing.

Filed: 2026-03-16

BioMarin has decided to discontinue dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency due to the occurrence of several slipped capital femoral epiphysis (SCFE) events in ongoing investigator-sponsored trials.
The Phase 2 CANOPY trials of VOXZOGO in children with Noonan syndrome, as well as those living with idiopathic short stature (ISS) without ACAN-deficiency, will continue as planned.
BioMarin has a strong safety profile for VOXZOGO, with no observed SCFE events in over 5,000 infants and children who have received the treatment for achondroplasia, or in its clinical trials for hypochondroplasia.

Filed: 2026-02-23

BioMarin Pharmaceutical Inc. (BMRN) reported its Q4 2025 financial results, providing an update on its operations and financial performance.
The company did not disclose any material agreements, leadership changes, or earnings surprises in this 8-K filing.
Without additional details on the company's financial results or other key business developments, the significance of this filing appears to be routine.

Filed: 2026-02-12

BioMarin Pharmaceutical Inc. completed a $850 million private placement of senior notes due in 2026 with an interest rate of 5.500% to fund the pending acquisition of Amicus Therapeutics, Inc.
The company also secured a new $2 billion senior secured term loan facility and a $800 million senior secured term loan facility, as well as a $600 million senior secured revolving credit facility, to finance the acquisition.
The indenture for the notes includes covenants that restrict BioMarin's ability to take certain actions, such as incurring additional debt, paying dividends, or making investments, unless certain conditions are met.

Filed: 2026-01-29

BioMarin is raising $850 million through a private placement of 5.500% senior unsecured notes due 2034 to help fund the acquisition of Amicus Therapeutics.
In addition to the notes offering, BioMarin has also secured a new $2 billion senior secured term loan facility and a $600 million senior secured revolving credit facility to finance the Amicus acquisition.
The notes will be guaranteed by certain of BioMarin's subsidiaries, including Amicus and its subsidiaries after the acquisition closes, and will rank equally with BioMarin's other unsubordinated debt.

Filed: 2026-01-26

BioMarin Pharmaceutical reported preliminary unaudited results for 2025, including total revenues of approximately $3.2 billion and VOXZOGO revenues of $920 million, indicating strong performance.
The company plans to raise $850 million through a private placement of senior unsecured notes due 2034 to fund its acquisition of Amicus Therapeutics, along with a new $2.8 billion senior secured credit facility.
The preliminary pro forma financial information provides insights into the expected impact of the Amicus Therapeutics acquisition on BioMarin's financial position and performance.

Other reports for BIOMARIN PHARMACEUTICAL INC

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.